YAKHAK HOEJI

Table. 5.

Table 5

Causal inference approach of the association of statin use with cirrhosis and hepatocellular carcinoma according to statin subclass

Outcome	Statin type (N)	IPW analysis		Superlearning TMLE
Outcome	Statin type (N)	Marginal OR^†	95% CI	Marginal OR^†	95% CI
By statin type
Cirrhosis	atorvastatin ( 11,867)	0.62^**	0.55-0.69	0.58^**	0.50-0.65
	rosuvastatin (2,482 )	0.60^**	0.43-0.77	0.59^**	0.48-0.70
	simvastatin ( 8,353)	0.66^**	0.57-0.76	0.63^**	0.52-0.71
	lovastatin (499 )	0.64^*	0.31-0.98	0.71^**	0.59-0.83
	pravastatin (2,402)	0.89	0.69-1.09	0.83	0.67-1.0
	fluvastatin (710)	1.19	0.64-1.74	0.96	0.82-1.12
	pitavastatin (1,729 )	0.80	0.56-1.04	0.72^**	0.57-0.86

Hepatocellular carcinoma	atorvastatin ( 11,867)	0.60^**	0.51-0.69	0.59^**	0.50-0.68
	rosuvastatin (2,482 )	0.51^**	0.37-0.66	0.62^**	0.50-0.74
	simvastatin ( 8,353)	0.71^**	0.60-0.84	0.69^**	0.56-0.81
	lovastatin (499 )	0.45^**	0.13-0.76	0.55^**	0.42-0.68
	pravastatin (2,402)	0.77^*	0.56-0.97	0.82	0.63-1.01
	fluvastatin (710)	0.97	0.45-1.46	0.99	0.80-1.18
	pitavastatin (1,729 )	0.72^*	0.45-0.99	0.68^**	0.51-0.86

^† Adjusted for dyslipidemia, cardiovascular disease, hypertension, cerebrovascular disease, diabetes mellitus, antihypertensive medication, antidiabetic medication, and lipid-lowering agents (except statin).

* p<0.05, ** p<0.01

Yakhak Hoeji 2024;68:44-55 https://doi.org/10.17480/psk.2024.68.1.44